1
|
Razzuoli E, Chirullo B, De Ciucis CG, Mecocci S, Martini I, Zoccola R, Campanella C, Varello K, Petrucci P, Di Meo A, Bozzetta E, Tarantino M, Goria M, Modesto P. Animal models of Soft Tissue Sarcoma for alternative anticancer therapy studies: characterization of the A-72 Canine Cell Line. Vet Res Commun 2023; 47:1615-1627. [PMID: 37038001 PMCID: PMC10484808 DOI: 10.1007/s11259-023-10115-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2023] [Accepted: 03/21/2023] [Indexed: 04/12/2023]
Abstract
Canine Soft Tissue Sarcoma (STS) cell line A-72 has been largely employed for antiviral and antiproliferative studies. However, there are few information on their characteristics. Our aim was to evaluate A-72 expression level of genes and proteins involved in the innate immune response and cell cycle, their ability to respond to infective stressors and their possible use as a cellular model for anti-cancer studies in human and animal medicine. For this purpose, we evaluated the basal expression of immune-related, cell cycle and DNA repair genes on this cell line and tumoral tissues. A-72 ability to respond to a wild-type strain of Salmonella typhimurium was assessed. S. typhimurium showed ability to penetrate A-72 causing pro-inflammatory response accompanied by a decrease of cell viability. IL10 and IL18 genes were not expressed in A-72 while CXCL8, NOS2, CXCR4 and PTEN were highly expressed in all samples and TP53 was slightly expressed, as shown in human STS. Our results outline the ability of A-72 to respond to a bacterial agent by modifying the expression of important genes involved in innate immune response and provide a useful model for in vitro evaluation of new therapeutic approaches that could be translated into the human oncology.
Collapse
Affiliation(s)
- Elisabetta Razzuoli
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Barbara Chirullo
- Unit of Emerging Zoonoses Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | - Chiara Grazia De Ciucis
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Samanta Mecocci
- Department of Veterinary Medicine, University of Perugia, Via San Costanzo 4, 06126 Perugia, Italy
| | - Isabella Martini
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Roberto Zoccola
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Chiara Campanella
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Katia Varello
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Paola Petrucci
- Unit of Emerging Zoonoses Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | - Antonio Di Meo
- Department of Veterinary Medicine, University of Perugia, Via San Costanzo 4, 06126 Perugia, Italy
| | - Elena Bozzetta
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Michela Tarantino
- Unit of Emerging Zoonoses Department of Food Safety, Nutrition and Veterinary Public Health, Istituto Superiore Di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
| | - Maria Goria
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| | - Paola Modesto
- National Reference Center of Veterinary and Comparative Oncology (CEROVEC), Istituto Zooprofilattico Sperimentale del Piemonte, Liguria E Valle D’Aosta, Piazza Borgo Pila 39/24, 16129 Genoa, Italy
| |
Collapse
|
2
|
Liu H, Lu Y, He Q, Cao X. Head and Neck Hemangiopericytoma: A Rare Case Report and Literature Review. EAR, NOSE & THROAT JOURNAL 2023:1455613231191379. [PMID: 37632344 DOI: 10.1177/01455613231191379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/28/2023] Open
Abstract
Hemangiopericytomas (HPCs) are rare vascular tumors, and head and neck hemangiopericytoma (HNHPC) accounts for 11% to 16% of all HPCs, possibly occurring at any age. However, according to a recent study, HNHPC was most frequently observed in middle-aged adults and had a slight predominance of female patients. In the present case, we report the successful treatment of HNHPC.
Collapse
Affiliation(s)
- Hanlin Liu
- The Fourth School of Clinical Medicine , Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Yuting Lu
- The Fourth School of Clinical Medicine , Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Qing He
- The Fourth School of Clinical Medicine , Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China
| | - Xiaolin Cao
- Department of Otorhinolaryngology and Head Neck Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
| |
Collapse
|
3
|
Poudel P, Shrestha S, Bhattachan M. Cerebral Hemangiopericytoma Manifesting as Epilepsia Partialis Continua: A Case Report. JNMA J Nepal Med Assoc 2022; 60:551-554. [PMID: 35690982 PMCID: PMC9275470 DOI: 10.31729/jnma.7410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2022] [Accepted: 05/30/2022] [Indexed: 11/01/2022] Open
Abstract
Cerebral hemangiopericytomas are very rare mesenchymal tumours arising from pericytes surrounding the blood vessels in the brain. Most patients present with headaches, focal neurological findings and focal seizures with or without generalisation. Our patient chiefly complained of an uncontrollable movement of her right hand that was initially fleeting but later became continuous. Her symptoms were initially described as tremors. We found an intracranial tumour as a cause of her symptoms, suspected the tumour to be a meningioma and performed surgical extirpation which resulted in symptom resolution. Histopathology and immunohistochemistry of the excised mass revealed that the tumour was hemangiopericytoma. The patient is being closely monitored for recurrences and metastasis. Hemangiopericytomas are very rare and they rarely result in the abnormal movements of epilepsia partialis continua. Differentiation of the abnormal movements of epilepsia partialis continua from tremors is very important as is the differentiation of the tumour from meningioma. Keywords case reports; epilepsia partialis continua; hemangiopericytoma; solitary fibrous tumors.
Collapse
Affiliation(s)
- Prabhat Poudel
- Nepal Medicai College and Teaching Hospital, Attarkhel, Kathmandu, Nepal,Correspondence: Dr Prabhat Poudel, Nepal Medical College and Teaching Hospital, Attarkhel, Kathmandu, Nepal. , Phone: +977-9843341484
| | - Sushan Shrestha
- Department of Neurosurgery, Kathmandu Medical College and Teaching Hospital, Sinamangal, Kathmandu, Nepal
| | - Maya Bhattachan
- Department of Neurosurgery, Nepal Medical College and Teaching Hospital, Attarkhel, Kathmandu, Nepal
| |
Collapse
|
4
|
Apra C, Guillemot D, Frouin E, Bouvier C, Mokhtari K, Kalamarides M, Pierron G. Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities. J Neurooncol 2021; 154:327-334. [PMID: 34417711 DOI: 10.1007/s11060-021-03830-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Accepted: 08/14/2021] [Indexed: 12/22/2022]
Abstract
INTRODUCTION Meningeal solitary fibrous tumors (SFT), like all SFT, are defined by NAB2-STAT6 fusion and share clinicopathologic similarities with meningiomas, the most frequent meningeal tumors. Our aim is to establish the molecular identity of meningeal SFT and seek molecular prognostic factors. METHODS RNA sequencing and whole exome sequencing were performed in STAT6-positive SFT and grade 2-3 meningiomas, and data concerning other soft tissues tumors was obtained from the local database. Uniform manifold approximation and projection, individual gene expression and Gene Set Enrichment Analysis were performed. RESULTS RNA clustering shows that SFT share a common molecular signature, different from any other type of tumoral tissue. Meningeal SFT aggregate with other SFT, with no clinical or histological subgroup. Comparison of genes expressions suggests significant over-expressions of ZIC2, ZIC3, ZIC5, GABBR2, TP53 in CNS-SFT. The pathogenic TP53 c.743G>T variant, previously undescribed in SFT, was found in one sample of meningeal SFT during malignant progression. CONCLUSIONS Meningeal SFT are molecular counterparts of extra-meningeal SFT, completely separate from meningiomas. They might develop from the same tissues and benefit from the same treatments as SFT.
Collapse
Affiliation(s)
- Caroline Apra
- Sorbonne Université, Paris, France.
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France.
- Paris Brain Institute, INSERM U1127, CNRS, UMR7225, 47-83 bd de l'Hôpital, 75013, Paris, France.
| | - Delphine Guillemot
- Pole of Diagnostic and Theranostic Medecine, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Eléonore Frouin
- Pole of Diagnostic and Theranostic Medecine, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| | - Corinne Bouvier
- Department of Pathology, APHM, CHU Timone, INSERM, MMG Aix Marseille University, Marseille, France
| | - Karima Mokhtari
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France
- Paris Brain Institute, INSERM U1127, CNRS, UMR7225, 47-83 bd de l'Hôpital, 75013, Paris, France
- Department of Neuropathology, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France
| | - Michel Kalamarides
- Sorbonne Université, Paris, France
- Department of Neurosurgery, Pitié-Salpêtrière Hospital, 47-83 bd de l'Hôpital, 75013, Paris, France
- Paris Brain Institute, INSERM U1127, CNRS, UMR7225, 47-83 bd de l'Hôpital, 75013, Paris, France
| | - Gaëlle Pierron
- Pole of Diagnostic and Theranostic Medecine, Institut Curie, 26 rue d'Ulm, 75005, Paris, France
| |
Collapse
|
5
|
Yamashita D, Suehiro S, Kohno S, Ohue S, Nakamura Y, Kouno D, Ohtsuka Y, Nishikawa M, Matsumoto S, Bernstock JD, Harada S, Mizuno Y, Kitazawa R, Ohnishi T, Kunieda T. Intracranial anaplastic solitary fibrous tumor/hemangiopericytoma: immunohistochemical markers for definitive diagnosis. Neurosurg Rev 2020; 44:1591-1600. [PMID: 32671693 DOI: 10.1007/s10143-020-01348-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Revised: 06/15/2020] [Accepted: 07/06/2020] [Indexed: 11/25/2022]
Abstract
Intracranial anaplastic hemangiopericytoma (AHPC) is a rare and malignant subset of solitary fibrous tumor/hemangiopericytoma (SFT/HPC) as per the WHO 2016 Classification of Tumors of the Central Nervous System. AHPC portends a poor prognosis and is associated with higher rates of recurrence/metastasis in comparison with SFT/HPC. Accordingly, it is critical to continue to define the clinical course of patients with AHPC and in so doing further refine clinicopathologic/immunohistochemical (IHC) criteria needed for definitive diagnosis. Herein, we describe clinical/histological characteristics of six patients with AHPC. In addition, we reviewed and analyzed the expression of various IHC markers reported within the literature (i.e., a total of 354 intracranial SFT/HPCs and 460 meningiomas). Histologically, tumors from our six patients were characterized by a staghorn-like vascular pattern, mitotic cells, and strong nuclear atypia. Immunohistochemically, all tumors displayed positive nuclear staining for STAT6; other markers, including CD34 and Bcl-2, were expressed only in three patients. Analysis of IHC expression patterns for SFT/HPC and meningioma within the literature revealed that nuclear expression of STAT6 had the highest specificity (100%) for SFT/HPC, followed by ALDH1 (97.2%) and CD34 (93.6%). Of note, SSTR2A (95.2%) and EMA (85%) displayed a high specificity for meningioma. Anaplastic SFT/HPC is a tumor with poor prognosis that is associated with higher rates of recurrence and metastasis in comparison with SFT/HPC. Given that anaplastic SFT/HPC requires more aggressive treatment than meningioma despite of a similar presentation on imaging, it is crucial to be able to distinguish between these tumors.
Collapse
Affiliation(s)
- Daisuke Yamashita
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan.
| | - Satoshi Suehiro
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan
| | - Shohei Kohno
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan.,Department of Neurosurgery, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan
| | - Shiro Ohue
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan.,Department of Neurosurgery, Stroke Center, Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan
| | - Yawara Nakamura
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan
| | - Daisuke Kouno
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan
| | - Yoshihiro Ohtsuka
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan
| | - Masahiro Nishikawa
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan
| | - Shirabe Matsumoto
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan
| | - Joshua D Bernstock
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard University, Boston, MA, USA
| | - Shuko Harada
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Yosuke Mizuno
- Division of Diagnostic Pathology, Ehime University Hospital, Toon, Ehime, Japan
| | - Riko Kitazawa
- Division of Diagnostic Pathology, Ehime University Hospital, Toon, Ehime, Japan
| | - Takanori Ohnishi
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan.,Department of Neurosurgery, Washoukai Sadamoto Hospital, Matsuyama, Ehime, Japan
| | - Takeharu Kunieda
- Department of Neurosurgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime, 791-0295, Japan
| |
Collapse
|
6
|
Low Expression of Phosphatase and Tensin Homolog and High Expression of Ki-67 as Risk Factors of Prognosis in Cranial Meningiomas. World Neurosurg 2019; 136:e196-e203. [PMID: 31887465 DOI: 10.1016/j.wneu.2019.12.108] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 12/17/2019] [Accepted: 12/18/2019] [Indexed: 12/14/2022]
Abstract
OBJECTIVE To investigate the expression characteristics, correlations with clinical factors, and prognostic values of phosphatase and tensin homolog (PTEN) and Ki-67 in cranial meningiomas. METHODS The expression of PTEN and Ki-67 at the mRNA level was analyzed in 34 frozen meningiomas. Clinical data collection, follow-up, correlations, and survival analyses were performed. RESULTS Twenty-two men and 12 women were included in the study, with a median age of 52.72 ± 11.72 years on admission. The average expression levels of PTEN and Ki-67 were 2.71 ± 1.73 and 0.50 ± 0.57, respectively. The World Health Organization grade III meningiomas exhibited significantly lower levels of PTEN (P = 0.037), whereas grade I meningiomas expressed significantly lower levels of Ki-67 (P = 0.001). For recurrent lesions, the mean Ki-67 expression level was 0.97 ± 0.76, which was significantly greater than that of primary meningiomas with a mean value of 0.25 ± 0.13 (P < 0.001). The Ki-67 expression level was positively correlated with the tumor volume (P < 0.01) and negatively correlated with preoperative Karnofsky Performance Status scale (KPS, P < 0.01), postoperative KPS (P < 0.05), and follow-up KPS (P < 0.01). However, the PTEN expression level did not correlate with these variables. Based on the multivariate Cox analysis, Ki-67 expression level (P < 0.001, hazard ratio [HR] 8.16, 95% confidence interval [CI] 2.86-23.29), and PTEN expression level (P = 0.018, HR 0.47, 95% CI 0.25-0.88) were independent prognostic factors for tumor recurrence. Ki-67 (P = 0.001, HR 19.73, 95% CI 3.65-106.61) and PTEN expression levels (P = 0.024, HR 0.36, 95% CI 0.15-0.88) were also independent prognostic factors for mortality. CONCLUSIONS A low PTEN expression and a high Ki-67 expression could predict malignancy in cranial meningiomas.
Collapse
|
7
|
Ciliberti MP, D'Agostino R, Gabrieli L, Nikolaou A, Sardaro A. The radiation therapy options of intracranial hemangiopericytoma: An overview and update on a rare vascular mesenchymal tumor. Oncol Rev 2018; 12:354. [PMID: 30101003 PMCID: PMC6068394 DOI: 10.4081/oncol.2018.354] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 06/20/2018] [Indexed: 12/05/2022] Open
Abstract
Hemangiopericytoma (HPC) is an extremely rare hypervascular tumor of mesenchymal lineage. It tends to recur and to develop distant metastases even many years after primary surgical resection. The management of recurrent and metastatic disease is not always so well defined. A complete surgical resection does not eliminate the high risk of local recurrences that occur in the central nervous system, often in the same surgical bed. However, treatment with adjuvant radiotherapy even in cases of complete resection remains controversial. Because of its rarity, there is no standard for treatment. We focused on radiotherapy treatment options, analyzing the literature and making a base on conduct further studies to establish the standard radiation dose to be used for locoregional control of such a complex and extremely rare disease and to help specialists to take the most appropriate therapeutic option.
Collapse
Affiliation(s)
- Maria Paola Ciliberti
- Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy
| | - Rosa D'Agostino
- Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy
| | - Laura Gabrieli
- Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy
| | - Anna Nikolaou
- Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy
| | - Angela Sardaro
- Department of Interdisciplinary Medicine, Section of Diagnostic Imaging and Radiotherapy, University Aldo Moro, Bari, Italy
| |
Collapse
|
8
|
Apra C, Mokhtari K, Cornu P, Peyre M, Kalamarides M. Intracranial solitary fibrous tumors/hemangiopericytomas: first report of malignant progression. J Neurosurg 2018. [DOI: 10.3171/2017.1.jns162593] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVEMeningeal solitary fibrous tumors/hemangiopericytomas (MSFTs/HPCs) are rare intracranial tumors resembling meningiomas. Their classification was redefined in 2016 by the World Health Organization (WHO) as benign Grade I fibrohyaline type, intermediate Grade II hypercellular type, and malignant highly mitotic Grade III. This grouping is based on common histological features and identification of a common NAB2-STAT6 fusion.METHODSThe authors retrospectively identified 49 cases of MSFT/HPC. Clinical data were obtained from the medical records, and all cases were analyzed according to this new 2016 WHO grading classification in order to identify malignant transformations.RESULTSRecurrent surgery was performed in 18 (37%) of 49 patients. Malignant progression was identified in 5 (28%) of these 18 cases, with 3 Grade I and 2 Grade II tumors progressing to Grade III, 3–13 years after the initial surgery. Of 31 Grade III tumors treated in this case series, 16% (5/31) were proved to be malignant progressions from lower-grade tumors.CONCLUSIONSLow-grade MSFTs/HPCs can transform into higher grades as shown in this first report of such progression. This is a decisive argument in favor of a common identity for MSFT and meningeal HPC. High-grade MSFTs/HPCs tend to recur more often and be associated with reduced overall survival. Malignant progression could be one mechanism explaining some recurrences or metastases, and justifying long-term follow-up, even for patients with Grade I tumors.
Collapse
Affiliation(s)
- Caroline Apra
- 1Sorbonne Universités, Université Pierre et Marie Curie; and
- Departments of 2Neurosurgery and
| | - Karima Mokhtari
- 1Sorbonne Universités, Université Pierre et Marie Curie; and
- 3Neuropathology, Pitié Salpêtrière Hospital, APHP, Paris, France
| | - Philippe Cornu
- 1Sorbonne Universités, Université Pierre et Marie Curie; and
- Departments of 2Neurosurgery and
| | - Matthieu Peyre
- 1Sorbonne Universités, Université Pierre et Marie Curie; and
- Departments of 2Neurosurgery and
| | - Michel Kalamarides
- 1Sorbonne Universités, Université Pierre et Marie Curie; and
- Departments of 2Neurosurgery and
| |
Collapse
|
9
|
Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma. Anal Cell Pathol (Amst) 2018; 2018:9718585. [PMID: 29707475 PMCID: PMC5863319 DOI: 10.1155/2018/9718585] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Accepted: 02/08/2018] [Indexed: 02/07/2023] Open
Abstract
Hemangiopericytoma (HPT) is a rare mesenchymal tumor of fibroblastic type and for its rarity is poorly studied. The most common sites of metastatic disease in patients with intracranial HPT are the bone, liver, and lung, suggestive for an hematogenous dissemination; for this reason, we investigated, for the first time, the presence of circulating tumor cells (CTCs) in hemangiopericytoma patient by CellSearch® and SceenCell® devices. Peripheral blood samples were drawn and processed by CellSearch, an EpCAM-dependent device, and ScreenCell®, a device size based. We found nontypical CTCs by CellSearch system and the immunofluorescence analysis performed on CTCs isolate by ScreenCell demonstrated the presence of single CTCs and CTC clusters. The molecular characterization of single CTCs and CTC clusters, using antibodies directed against EpCAM, CD34, cytokeratins (8, 18, and 19), and CD45, showed a great heterogeneity in CTC clusters. We believe that the present study may open a new scenario in the rare tumors: the introduction of the liquid biopsy and the molecular characterization of circulating tumor cells could lead to personalized targeted treatments and also for rare tumors.
Collapse
|
10
|
Jeon SH, Park SH, Kim JW, Park CK, Paek SH, Kim IH. Efficacy of adjuvant radiotherapy in the intracranial hemangiopericytoma. J Neurooncol 2018; 137:567-573. [DOI: 10.1007/s11060-018-2746-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2017] [Accepted: 01/05/2018] [Indexed: 01/10/2023]
|
11
|
Gulwani H, Shukla P, Kaur S, Shanmugasundaram D. Reappraisal of morphological and immunohistochemical spectrum of intracranial and spinal solitary fibrous tumors/hemangiopericytomas with impact on long-term follow-up. Indian J Cancer 2018; 55:214-221. [DOI: 10.4103/ijc.ijc_631_17] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
12
|
The impact of postoperative radiation therapy on patterns of failure and survival improvement in patients with intracranial hemangiopericytoma. J Neurooncol 2015; 127:181-90. [DOI: 10.1007/s11060-015-2030-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2015] [Accepted: 12/25/2015] [Indexed: 10/22/2022]
|